What guidance did Rigel Pharmaceuticals's management provide for the next earnings period?

What were the key takeaways from Rigel Pharmaceuticals's earnings call?

What is Rigel Pharmaceuticals's gross profit margin?

What is Rigel Pharmaceuticals's latest dividend and current dividend yield?

What is the revenue and EPS growth rate for Rigel Pharmaceuticals year over year?

What does Rigel Pharmaceuticals do and what are its main business segments?

What factors drove the changes in Rigel Pharmaceuticals's revenue and profit?

Did Rigel Pharmaceuticals beat or miss consensus estimates last quarter?

- **Revenue Surge**: 2025 net product sales hit $232M (+60% YoY), driven by TAVALISSE, GAVRETO, and REZLIDHIA.
- **R289 Breakthrough**: 33% of evaluable MDS patients achieved transfusion independence in Phase Ib study.
- **Financial Strength**: 2025 GAAP net income of $367M, with 2026 guidance for $275-290M revenue and positive net income.
- **Strategic Expansion**: Pursuing late-stage in-licensing deals and advancing R289 toward potential registration.

**【CEO Summary Section】**
- RIGL has transformed from a single-product company to a portfolio of 3 commercial drugs (TAVALISSE, REZLIDHIA, GAVRETO) with 4 indications, achieving a 35% CAGR in net product sales since 2022.
- 2025 net product sales reached $232M, up 60% YoY, driven by TAVALISSE ($45.6M Q4, +47% YoY), GAVRETO ($10.2M Q4, +27% YoY), and REZLIDHIA ($9.6M Q4, +29% YoY).
- R289, a dual IRAK1/4 inhibitor, showed promising Phase Ib data in lower-risk MDS with 33% of evaluable patients achieving transfusion independence for ≥8 weeks.
- 2026 guidance: $275-290M total revenue, with focus on in-licensing late-stage assets and advancing R289 toward potential registration.

**【CFO Financial Commentary】**
- Q4 2025 GAAP net income: $268.1M (vs. $14.3M YoY), driven by $245.9M non-cash deferred tax benefit.
- Full year 2025 net income: $367M (vs. $17.5M YoY), with cash position increasing to $155M from $77.3M.
- 2026 financial outlook: Positive net income with disciplined capital allocation for clinical development.

**【Q&A Key Highlights】**
- **TAVALISSE Growth**: 47% Q4 YoY growth due to new patient starts; virtual sales team pilot expanded reach.
- **GAVRETO Reintroduction**: 2025 sales exceeded prior company's $28-30M, now targeting stable growth through targeted oncology/hematology engagement.
- **R289 Dosing**: Exploring 500mg QD vs. BID in Phase Ib; no preference yet, data-driven decision expected H2 2026.
- **Business Development**: Actively pursuing late-stage in-licensing opportunities (NDA-ready or approved) in hem/onc, with focus on 2028 launch timeline.

Rigel Pharmaceuticals, Inc.(RIGL)-20260304-2025 Q4 Earnings call transcript

- **Revenue Surge**: Q3 2025 net product sales of $64.1 million (+65% YoY), driving total revenue to $69.5 million. Updated 2025 guidance: $285-$290 million, up 55%-59% YoY.
- **Pipeline Momentum**: R289 phase 1b dose expansion underway; olutasidenib advancing into glioma and first-line AML/MDS via strategic trials.
- **Financial Strength**: $27.9 million net income, $137.1 million cash, and cost control supporting growth.
- **Strategic Expansion**: Global partnerships (e.g., Kissei, Dr. Reddy’s) and collaborations (MD Anderson, Connect) fueling pipeline and commercial reach.

**【CEO Summary Section】**
- **Revenue Growth**: Total revenue of $69.5 million, with net product sales at $64.1 million, a 65% year-over-year increase. TAVALISSE, GAVRETO, and REZLIDHIA contributed $44.7 million, $11.1 million, and $8.3 million respectively.
- **Pipeline Progress**: R289 phase 1b study in lower-risk MDS nearing dose expansion phase; olutasidenib expanding into glioma and first-line AML/MDS via collaborations with MD Anderson, Connect, and MyloMATCH.
- **Updated Guidance**: 2025 revenue raised to $285-$290 million, with net product sales expected at $225-$230 million, reflecting 55%-59% YoY growth.

**【CFO Financial Commentary】**
- **Financial Health**: Net income of $27.9 million, cash balance of $137.1 million, and cost control leading to $41 million in total costs (down from $41.3 million YoY).
- **Revenue Breakdown**: Contract revenues of $5.4 million from collaborations, including $3.1 million from Grifols and $1.8 million from Kissei.
- **Cost Efficiency**: Favorable gross-to-net dynamics and improved patient access driving commercial performance.

**【Q&A Highlights】**
- **R289 Strategy**: Dose expansion phase comparing 500mg BID and 1000mg QD; potential registrational study design to be determined post-FDA discussions.
- **Glioma Collaboration**: Connect study evaluating olutasidenib as maintenance therapy in high-grade glioma, targeting underserved adolescent and young adult patients.
- **Competitive Positioning**: R289's dual IRAK1/4 inhibition offers unique anti-inflammatory mechanism, differentiating it from HMAs and ESAs in lower-risk MDS.

Rigel Pharmaceuticals, Inc. (RIGL) Q3 2025 Earnings Call Transcript

- **Revenue Surges 76% YoY**: Q2 2025 net product sales hit $58.9M, driven by TAVALISSE (+52%), GAVRETO (+32%), and REZLIDHIA (+36%).
- **Guidance Raised to $280M**: 2025 total revenue outlook increased 35% to $270-280M, reflecting 45-52% YoY growth in net product sales.
- **Pipeline Momentum**: R289 Phase 1b MDS study completes dose escalation; olutasidenib glioma trial design to be disclosed.
- **Financial Strength**: $59.6M net income, $108.4M cash balance, and no debt, enabling strategic investments.
- **Affordability Impact**: IRA reforms boosted patient access, contributing to record new patient starts for TAVALISSE.

**【CEO Opening Remarks】**
- Q2 2025 net product sales reached $58.9 million, a 76% YoY increase, driven by TAVALISSE ($40.1M, +52%), GAVRETO ($11.8M, +32%), and REZLIDHIA ($7M, +36%).
- Total revenue guidance raised to $270-280 million (prev: $200-210M), with net product sales expected to grow 45-52% YoY.
- $40M non-cash collaboration revenue recognized from Lilly's RIPK1 inhibitor program.
- Cash balance increased to $108.4 million, up from $77.3M at year-end 2024.

**【Chief Commercial Officer (Dave Santos)】**
- TAVALISSE growth fueled by improved patient affordability under the Inflation Reduction Act (IRA), with new patient starts at record levels.
- GAVRETO expanded awareness in frontline RET+ thyroid cancer, with 32% Q/Q revenue growth.
- REZLIDHIA's ASCO data highlighted earlier use in relapsed/refractory IDH1+ AML, driving 36% YoY sales growth.
- International expansion: TAVALISSE launched in South Korea, REZLIDHIA partnerships in Asia and with Dr. Reddy's.

**【Chief Medical Officer (Lisa Rojkjaer)】**
- R289 Phase 1b MDS study completed dose escalation in July; updated data expected later this year.
- Olutasidenib collaborations: 
  - CONNECT's TarGeT-D trial evaluating maintenance therapy in IDH1+ glioma.
  - MD Anderson trials in IDH1+ AML/MDS.
- R289 has Fast Track and Orphan Drug Designations, with potential 7-year exclusivity.

**【Chief Financial Officer (Dean Schorno)】**
- Q2 2025 financials:
  - Net income: $59.6M (vs. $1M loss in Q2 2024).
  - Total revenue: $101.7M (including $42.7M collaboration revenue).
  - Cost of product sales: $4.5M; R&D expenses up due to clinical trial timing.
- 2025 guidance: 
  - Total revenue: $270-280M (prev: $200-210M).
  - Contract revenue: $60M (prev: $15-18M).

**【Q&A Highlights】**
- **TAVALISSE Growth Drivers**: 52% YoY increase attributed to new patient starts (+70% YoY) and carryover demand, enabled by IRA's $2,000 annual OOP cap.
- **Pipeline Strategy**: R289 dose expansion phase expected Q3 2025; olutasidenib glioma study design to be disclosed later this year.
- **Market Expansion**: No immediate plans for additional in-licensing, but open to late-stage assets fitting Rigel's commercial infrastructure.
- **Financial Leverage**: Strong cash position ($108.4M) supports clinical development while maintaining profitability.


Rigel Pharmaceuticals, Inc. (RIGL) Q2 2025 Earnings Call Transcript

- **Revenue Growth Supercharge**: Q1 2025 net product sales surge 68% YoY to $43.6M, driven by TAVALISSE (+35%), GAVRETO (+15%), and REZLIDHIA (+25%).
- **Pipeline Momentum**: R289 shows 40% transfusion independence in MDS; olutasidenib Phase II glioma trial set for Q2 2025.
- **Financial Health**: $11.4M net income vs. $8.2M loss YoY; $77.1M cash runway supports 2025 guidance of $200-210M revenue.
- **Strategic Shifts**: Exiting Lilly's RIPK1 program to focus on core hem/onc assets; no near-term generic threats to TAVALISSE.


**【CEO Opening Remarks】**
- Q1 2025 total revenue reached $53.3 million, with net product sales growing 68% YoY to $43.6 million.
- Key products: TAVALISSE (+35% YoY), GAVRETO (+15% YoY), and REZLIDHIA (+25% YoY).
- 2025 full-year guidance: $200-210 million revenue, positive net income, and $185-192 million in net product sales.
- Strategic focus: commercial growth, pipeline advancement (R289, olutasidenib), and financial discipline.

**【CFO Financial Highlights】**
- Q1 2025 net income: $11.4 million (vs. $8.2 million loss in Q1 2024).
- Cost of product sales: $4.4 million, driven by royalty expenses and API costs.
- R&D expenses: $22.1 million, up 53% YoY due to clinical trial expansion.
- Cash position: $77.1 million, stable from Q4 2024.
- Non-cash collaboration revenue of $40 million expected in Q2 from Lilly opt-out.

**【CMO Pipeline Updates】**
- **R289 (IRAK1/4 inhibitor):** Phase Ib study in lower-risk MDS shows 40% transfusion independence at 500mg BID, with 29-week median duration.
- **Olutasidenib (IDH1 inhibitor):** Q2 2025 Phase II trial planned for recurrent glioma; collaboration with MD Anderson and CONNECT for additional trials.
- **Ocadusertib (RIPK1 inhibitor):** Lilly partnership continues, with Phase IIa/IIb rheumatoid arthritis trial ongoing.

**【CCO Commercial Performance】**
- TAVALISSE: Record-high patient demand, 35% YoY growth.
- GAVRETO: $9 million in Q1, 11% sequential growth post-Rigel acquisition.
- REZLIDHIA: 25% YoY growth, focus on post-venetoclax AML market.
- Global expansion: TAVALISSE approved in Korea and Mexico; REZLIDHIA partnerships in Japan, Korea, Taiwan.

**【Q&A Key Takeaways】**
- **Litigation Risk:** No active ANDA filers for TAVALISSE beyond Annora (entry Q2 2032).
- **Pipeline Strategy:** Prioritizing internal assets (R289, olutasidenib) over Lilly's RIPK1 program.
- **Regulatory Path:** Seeking FDA input on R289 Phase II dose selection via Project Optimus.
- **Market Dynamics:** Inflation Reduction Act compliance maintained; no material impact on Q1 demand.


Rigel Pharmaceuticals (RIGL)-6 May 25-2025 Q1 Earnings call transcript

- **Record 2024 Performance**: $145M net product sales (39% YoY), first-year profitability ($17M net income).
- **2025 Growth Targets**: 30% YoY sales growth to $185-192M, fueled by TAVALISSE, REZLIDHIA expansion.
- **Pipeline Momentum**: R289 MDS Phase Ib shows 3/18 patients transfusion-free >6 months; glioma trial planned for 2025.
- **Operational Excellence**: Seamless GAVRETO transition achieved 100% patient retention, $8.1M Q4 sales.


**【CEO Summary Section】**
- Rigel reported record 2024 net product sales of $145 million, up 39% YoY, driven by TAVALISSE ($31M Q4), REZLIDHIA ($7.4M Q4), and GAVRETO ($8.1M Q4). 
- Full-year net income of $17M marked first year of profitability, with cash balance increasing by $20M to $77.3M.
- 2025 guidance: $185-192M net product sales (30% YoY growth), with plans to initiate Phase II glioma trial and expand R289 MDS study.

**【CFO Financial Commentary】**
- Q4 2024 net product sales: $46.5M (58% YoY growth), including $11.1M in collaboration revenues.
- Full-year 2024 total revenue: $202.1M; net income: $17.5M vs. $25.1M loss in 2023.
- 2025 financial outlook: $200-210M total revenue, with continued focus on profitable growth.

**【Commercial Update】**
- TAVALISSE: Q4 net sales $31M (21% YoY), 9th consecutive quarterly volume high.
- REZLIDHIA: Q4 net sales $7.4M (92% YoY), doubling 2023 sales.
- GAVRETO: Seamless transition achieved $8.1M Q4 sales, surpassing prior owner's 2023 run rate.

**【Pipeline Progress】**
- R289 (IRAK1/4 inhibitor): Phase Ib MDS study shows 3/18 patients achieving transfusion independence >6 months.
- Olutasidenib (IDH1 inhibitor): New Phase II glioma trial planned for 2025; 4 MD Anderson trials now enrolling.
- RIPK1 inhibitor (with Lilly): Phase IIa rheumatoid arthritis trial enrolling ~100 patients.

**【Q&A Highlights】**
- 2025 sales growth: 30% YoY driven by TAVALISSE, REZLIDHIA expansion, and GAVRETO momentum.
- REZLIDHIA duration: Early adopters show longer therapy durations as earlier-line use increases.
- GAVRETO transition: 100% patient retention achieved, with new prescribers driving growth.
- R289 regulatory path: Fast Track and Orphan Drug designations support 2025 Phase II expansion.


Actual											1.3	-1	-0.8	-1.1	2.2	-0.8	-1.2	-1.3	-1.6	-0.8	-1.1	0.1	-0.8	-0.4	-0.3	0	-0.5	-0.06	0.7	0.8	0.63	3.28	1.46	13.54
Forecast											1.3154	-1.3345	-1.217	-1.1196	0.0488	-1.0932	-0.9964	-1.2682	-1.3697	-1.2268	-1.3221	-0.9469	-0.9578	-0.7803	-0.7099	-0.2037	-0.288	-0.2921	0.0585	0.4508	0.0893	2.58	0.8997	1.2015
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-1.17%	+25.07%	+34.26%	+1.75%	+4408.20%	+26.82%	-20.43%	-2.51%	-16.81%	+34.79%	+16.80%	+110.56%	+16.48%	+48.74%	+57.74%	+100.00%	-73.61%	+79.46%	+1096.58%	+77.46%	+605.49%	+27.13%	+62.28%	+1026.92%

RIGL

RIGL fundamentals

RIGL Q4 2025 Earnings

Earnings Call

You can ask Aime

RIGL

RIGL fundamentals

RIGL Q4 2025 Earnings

Earnings Call

RIGL Earnings Call Summary for Q4/20254:30 PM on Mar 3, 2026

RIGL Earnings Call Summary for Q3/20254:30 PM on Nov 4, 2025

RIGL Earnings Call Summary for Q2/20254:30 PM on Aug 5, 2025

RIGL Earnings Call Summary for Q1/20254:30 PM on May 6, 2025

RIGL Earnings Call Summary for Q4/20244:30 PM on Mar 4, 2025

You can ask Aime